« Return to News | CROs/Service Providers

ICON Report Highlights Need for Resources to Meet New Safety Regulations

Wednesday, June 24, 2009 08:59 AM

A new report released by ICON last week says new safety regulations have created a greater demand for resources to ensure those regulations are met.

The report is based on a survey, commissioned by ICON and market intelligence firm IMS Health, of 140 industry safety specialists within large and mid-size pharmaceutical companies. 

According to "Safety First: The Impact of New Regulations on Clinical Development," 77% of respondents said new safety regulations have had a considerable impact on the drug development industry, and 53% of those surveyed highlighted their regulatory departments in particular as requiring resources within the next six months.

Respondents to the survey said they anticipate phase IV trial activity will grow in the next five years, and 58% said that safety registries increasingly will be used to monitor drug safety at every stage of the clinical trial process.

"The move toward greater transparency around drug safety remains a regulatory and political priority worldwide," said Nigel Burrows, senior principal, management consulting, IMS. "The pharmaceutical industry has and continues to respond to this challenge, both in drug clinical development and commercialization. These efforts have the potential to go beyond simply satisfying regulatory requirements, leading to more clinically effective and commercially viable advances that improve outcomes and set new standards of care."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.